According to the press release, Genfit presented advancements in its pipeline focused on ACLF (Acute-on-Chronic Liver Failure) during the annual event The Liver Meeting organized by the AASLD (American Association for the Study of Liver Diseases).
Major Platform for Innovative Approaches
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Genfit stated that the 2025 edition of The Liver Meeting, a key event for liver specialists, served as a platform for showcasing these advancements. The company detailed its innovative approach to treating ACLF, a severe condition that requires new therapeutic options.
Strengthening Market Position
The company believes that the progress made in its ACLF pipeline could strengthen its position in the field of hepatic medicine. The Liver Meeting 2025 also allowed Genfit to reiterate its commitment to innovation in the treatment of liver diseases.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
Context
Period
Period: 1T2026
Key reported figures
Revenue: 9.6M€
Risks mentioned
Dépendance aux partenaires pour le développement commercial.
Opportunities identified
Dynamique favorable des ventes d'Iqirvo renforçant les marges financières.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
